Skip to Main Content

Paper Details

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.
Clin Cancer Res
26
2016
C, Full-length MET, GTL-16, HGF, MET, PF02341066, PHA665752, SNU5, Tyrosine, Tyrosine Kinase, VEGFR, amplified cancers, biopsies, cancer, crizotinib, full-length MET, gastric carcinoma, gastric carcinoma xenografts, hereditary papillary renal carcinoma, human, pMET, pY1234, pY1234/1235 MET, pY1235, pY1235-MET, pY1356, pY1356-MET, pazopanib, tivantinib, tumor
Author NameAffiliation
Yvonne A EvrardInc., Frederick National Laboratory for Cancer Research
William Marston Linehan
James H Doroshow
James H Doroshow
  • 1 - 4

Datasets

Release 1.2